Therapeutic substance delivery device and delivery system based on interventional mode

By using a support stent or luminescent components to maintain the dilation of blood vessels in an interventional therapeutic substance delivery device, the problem of contraction of blood vessels during drug delivery is solved and the treatment effect is improved.

CN118987463APending Publication Date: 2024-11-22HANGZHOU MATRIX MEDICAL TECH CO LTD
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202411090786.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

When delivering drugs to the vascular endothelial injury site, blood vessels are prone to contraction, resulting in unsatisfactory treatment results.

Method used

An interventional delivery device is designed, using a support frame or a light emitting component as a retaining component to keep the blood vessels in an expanded state when delivering drugs and avoid contraction. The device includes an outer sheath, a tube assembly, a sealing assembly and a retaining assembly, which exerts an expansion effect at the delivery position through a support frame or a light emitting member to ensure that the blood vessels remain in the necessary expansion state.

Benefits of technology

It effectively avoids vasoconstriction, improves the effect of drug treatment, keeps the blood vessels stretched when delivering drugs, and enhances the effect of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987463A_ABST
    Figure CN118987463A_ABST
Patent Text Reader

Abstract

The invention relates to a therapeutic substance delivery device and delivery system based on an intervention mode, and the therapeutic substance delivery device comprises an outer sheath which is of a tubular structure and is provided with a far end and a near end which are opposite to each other, and the outer sheath is internally provided with a therapeutic substance delivery channel; the tube assembly is movably arranged in the outer sheath; the plugging assembly comprises a first balloon and a second balloon which are sequentially arranged in the axis direction of the outer sheath and used for temporarily blocking blood flow, and the position between the first balloon and the second balloon is an expected therapeutic substance conveying position; the keeping assembly is used for keeping the blood vessel at the expected therapeutic substance conveying position in an expanded state, and the keeping assembly adopts one of the following structures: a, a support frame; and b, a light-emitting component. According to the interventional-mode-based therapeutic substance delivery device and delivery system provided by the invention, when drugs are delivered to an endothelial injury part, blood vessels are prevented from being shrunk, and drug therapy is carried out in a blood vessel stretching state, so that the treatment effect is better.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of medical device technology, and in particular to an interventional-based therapeutic delivery device and delivery system. Background Art

[0002] Cardiovascular diseases such as hypertension and coronary heart disease will cause vascular endothelial damage to patients. In order to repair vascular endothelial damage, a variety of methods can be used. One of them is to deliver drugs to the site of endothelial damage through interventional means. The damaged site of the endothelium itself is prone to stenosis and is more likely to contract under the stimulation of drugs. Vascular repair under the condition of vascular contraction is not ideal. Summary of the invention

[0003] Based on this, an interventional therapeutic delivery device and delivery system are provided, which can prevent blood vessels from contracting when delivering drugs to the site of endothelial damage, thereby improving the drug treatment effect.

[0004] A therapeutic substance delivery device based on an interventional approach, comprising:

[0005] An outer sheath is a tubular structure having a distal end and a proximal end opposite to each other, and the interior of the outer sheath has a therapeutic substance delivery channel;

[0006] a tube assembly, movably disposed in the outer sheath;

[0007] The blocking component includes a first balloon and a second balloon which are sequentially arranged along the axis direction of the outer sheath and are used to temporarily block the blood flow, and the area between the first balloon and the second balloon is the expected delivery position of the therapeutic substance;

[0008] A holding component is used to keep the blood vessel at the intended delivery position of the therapeutic substance in an expanded state, wherein the holding component adopts one of the following structures:

[0009] a. A support frame, which is a radially deformable cylindrical structure as a whole, and has a loaded state in which it can be accommodated in the outer sheath and an expanded state exposed to the distal side of the outer sheath;

[0010] b. A light-emitting component fixed to the tube assembly, wherein the light-emitting component has a working portion located within the expected delivery position of the therapeutic substance, and the working portion is used to output a first light with a wavelength range of 400 to 1200 nm.

[0011] Several optional methods are also provided below, but they are not intended to be additional limitations on the above-mentioned overall solution, but are merely further supplements or preferences. Under the premise that there are no technical or logical contradictions, each optional method can be combined with the above-mentioned overall solution separately, and multiple optional methods can also be combined.

[0012] Optionally, the wavelength range of the first light is 600-850 nm.

[0013] Optionally, the first balloon is located at the periphery of the distal end of the outer sheath;

[0014] The second balloon, the distal end of the tube assembly has an extension portion extending out of the outer sheath, the second balloon is located at the periphery of the extension portion, and the first balloon and the second balloon are respectively located upstream and downstream of the expected delivery position of the therapeutic substance along the blood flow direction.

[0015] Optionally, a first fluid channel connected to the first balloon is provided in the side wall of the outer sheath for conveying fluid to the first balloon.

[0016] Optionally, the outer sheath is a double-layer tube structure and has an inner lumen and an outer lumen that are radially opposite, wherein the inner lumen serves as a channel of the tube assembly, and the outer lumen separates and forms a first fluid channel for delivering fluid to the first balloon and a therapeutic substance delivery channel for delivering the therapeutic substance to the intended delivery position of the therapeutic substance.

[0017] Optionally, the support frame is made of memory material, and the tubular structure of the support frame is a hollow grid, which switches from a loaded state to an expanded state by self-expansion after being exposed to the outer sheath.

[0018] Optionally, the tube assembly comprises:

[0019] an inner tube, wherein the lumen of the inner tube provides a guide wire passage;

[0020] The outer tube is sleeved on the outside of the inner tube, the distal end of the outer tube is connected to the second balloon, and the radial gap between the outer tube and the inner tube serves as a second fluid channel connected to the second balloon.

[0021] Optionally, the light-emitting component is an optical fiber or a Micro LED, the light-emitting component is located in a radial gap between the inner tube and the outer tube, the light-emitting component is fixed to the outer wall of the inner tube, and extends toward the proximal end along the second fluid channel.

[0022] Optionally, the therapeutic substance delivery device as a whole has:

[0023] Working state, in which each balloon is inflated with fluid and exposed to the outer sheath, the support frame is exposed to the outer sheath in an expanded state, or the working part of the light-emitting component is at the expected delivery position of the therapeutic substance to emit light;

[0024] Delivery state, in the delivery state, the shapes of the balloons are folded and stored in the outer sheath, the support frame is stored in the outer sheath and is in a loading state, or the light-emitting component is stored in the outer sheath and does not emit light.

[0025] The present application also provides a delivery system for therapeutic substances based on an interventional approach, comprising:

[0026] The therapeutic substance delivery device;

[0027] a first perfusion device, used for providing a therapeutic substance to be delivered into the blood vessel and connected to the therapeutic substance delivery channel;

[0028] The second perfusion device is connected to the first balloon and the second balloon respectively through fluid pipelines.

[0029] The interventional therapeutic substance delivery device and delivery system provided in the present application prevents blood vessels from contracting when delivering drugs to sites of endothelial damage, and performs drug treatment in a state of vascular dilation, resulting in better treatment effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1a This is a schematic diagram of the therapeutic substance delivery device based on the interventional method of the present application (the holding component adopts a light-emitting component);

[0031] Figure 1b for Figure 1a A magnified view of part A in FIG.

[0032] Figure 2a Schematic diagram of the therapeutic substance delivery device based on the interventional method of the present application (the holding component adopts a support frame);

[0033] Figure 2b for Figure 2a A magnified view of part B in FIG.

[0034] Figure 3 A schematic diagram of a first balloon and its supporting components in the therapeutic substance delivery device based on an interventional approach of the present application;

[0035] Figure 4 for Figure 3 The enlarged view of the C part in FIG.

[0036] Figure 5 This is a schematic diagram of a second balloon and its supporting components in the therapeutic substance delivery device based on an interventional approach of the present application (the holding component adopts a support frame);

[0037] Figure 6 for Figure 5 The enlarged view of the D part in FIG.

[0038] Figure 7 A schematic diagram of one embodiment of a support frame;

[0039] Figure 8 This is a schematic diagram of a second balloon and its supporting components in the therapeutic substance delivery device based on an interventional approach of the present application (the holding component adopts a light-emitting component);

[0040] Fig. 9 for Figure 8 Enlarged view of part E in .

[0041] In the figure: 100, therapeutic delivery device; 110, outer sheath; 111, first fluid channel; 112, therapeutic delivery channel; 113, inner cavity; 114, outer cavity; 120, support frame; 130, tube assembly; 131, inner tube; 132, outer tube; 133, second fluid channel; 140, light-emitting component; 150, blocking assembly; 151, first balloon; 152, second balloon; 171, first handle; 1711, first interface; 1712, second interface; 1713, third interface; 172, second handle; 1721, fourth interface; 1722, fifth interface; 180, guide wire channel; 190, developing ring.

[0042] Y, distal; J, proximal. DETAILED DESCRIPTION

[0043] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0044] In order to better describe and illustrate the embodiments of the present application, reference may be made to one or more drawings, but the additional details or examples used to describe the drawings should not be considered as limiting the scope of the invention of the present application, any of the currently described embodiments or preferred methods.

[0045] It should be noted that when a component is referred to as being "connected" to another component, it may be directly connected to the other component or there may be a central component. When a component is referred to as being "disposed on" another component, it may be directly disposed on the other component or there may be a central component at the same time.

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0047] See also Figure 1a , Figure 1b , Figure 2a , Figure 2b As shown, the therapeutic substance delivery device 100 based on the interventional approach comprises:

[0048] The outer sheath 110 is a tubular structure having a distal end and a proximal end opposite to each other, and the inner part of the outer sheath has a therapeutic substance delivery channel;

[0049] A tube assembly 130 movably disposed in the outer sheath 110 ;

[0050] The blocking component 150 includes a first balloon 151 and a second balloon 152 which are sequentially arranged along the axial direction of the outer sheath 110 and are used to temporarily block the blood flow, and the area between the first balloon 151 and the second balloon 152 is the expected delivery position of the therapeutic substance;

[0051] The holding component is used to keep the blood vessel at the intended delivery position of the therapeutic substance in an expanded state, and the holding component adopts one of the following structures:

[0052] a. The support frame 120 is a radially deformable cylindrical structure as a whole, and has a loaded state that can be accommodated in the outer sheath 110 and an expanded state that is exposed to the distal side of the outer sheath 110 ( Figure 2a , Figure 2b The middle support frame is in the expanded state);

[0053] b. The light emitting component 140 is fixed to the tube assembly 130. The light emitting component 140 has a working portion located within the expected delivery position of the therapeutic substance, and the working portion is used to output a first light with a wavelength range of 400 to 1200 nm.

[0054] The therapeutic substance delivery device provided in the present application is used to deliver a therapeutic substance to a desired part. During the process of delivering the therapeutic substance, the blood vessels at the desired part are narrowed, or contracted due to stimulation during the process of delivering the drug. In order to keep the blood vessels at the desired part in the necessary expansion state during the process of delivering the drug, a holding component is provided in the therapeutic substance delivery device. The holding component can adopt two structures, namely a support frame and a light-emitting component. Both structures can play a role in keeping the blood vessels in an expanded state. Only one of them can be selected. When the support frame and the light-emitting component are mentioned below, it is based on this premise, that is, the support frame and the light-emitting component do not exist at the same time, and only one of them can exist. Figure 1a , Figure 1b This is a schematic diagram of using a light-emitting component as a holding component. Figure 2a , Figure 2b A schematic diagram of using a support frame to retain the component.

[0055] When the holding component is a support frame, the working process of the therapeutic substance delivery device provided by the present application is as follows:

[0056] During the delivery process, the support frame 120, the tube assembly 130 and the occluding assembly 150 are all housed in the outer sheath 110 (the support frame 120 is located in the radial gap between the tube assembly 130 and the outer sheath 110). After reaching the target site, the tube assembly 130 extends out of the outer sheath 110, and the support frame 120 is exposed to the distal side of the outer sheath 110, and switches to an expanded state to support the blood vessels at the target site and deliver the therapeutic agent to the target site for treatment. During the treatment process, the support frame is always maintained in an expanded state. After the treatment is completed, the support frame 120 is not left in the target site for a long time, but is withdrawn from the blood vessels at the target site.

[0057] One structural form of the support frame 120 is shown in Figure 7 As shown, the support frame 120 has a hollow grid structure, the support frame 120 is compressible in the radial direction, the distal end of the support frame 120 is an open structure, and the proximal end of the support frame 120 is gathered into a line and then extends out of the proximal end of the outer sheath 110. The support frame 120 and the tube assembly 130 are not fixedly connected. During the delivery process, a movable connection can be set between the support frame 120 and the tube assembly 130 (for example, a protrusion is provided on the outer wall of the tube assembly, which can push the support frame 120 to move. The movable connection here is understood to mean that the two have a mutual force, rather than a substantial connection relationship), so that when the tube assembly 130 extends out of the outer sheath 110, it can drive the support frame 120 to be exposed to the outer sheath 110. On the distal end, when the support frame 120 is radially expanded and in an expanded state, the connection between the support frame 120 and the tube assembly 130 is disconnected. After the support frame 120 is released, the drug is delivered to the blood vessel at the intended location for treatment. During the treatment, the first balloon 151 and the second balloon 152 can be withdrawn from the blood vessel at the target location first, leaving only the support frame 120 at the target location to prevent long-term obstruction of blood flow. At the same time, when the first balloon 151 and the second balloon 152 are withdrawn, since the support frame 120 still stays at the target location to play a supporting role, further damage to the inner wall of the blood vessel caused by the withdrawal of the first balloon 151 and the second balloon 152 can be avoided.

[0058] When the treatment is completed and the support frame 120 needs to be withdrawn, a sheath can be pushed onto the support frame 120. Under the force of the sheath, the support frame 210 radially contracts into the sheath, and the sheath drives the support frame 120 away from the target site.

[0059] When the holding component is a light-emitting component, the working process of the therapeutic substance delivery device provided by the present application is as follows:

[0060] During the delivery process, the light-emitting component 140, the tube assembly 130 and the blocking component 150 are all housed in the outer sheath 110 (the support frame 120 is located in the radial gap between the tube assembly 130 and the outer sheath 110). After reaching the target site, the tube assembly 130 extends out of the outer sheath 110, and the light-emitting component 140 extends out of the outer sheath 110 along with the tube assembly 130, and applies a first light with a wavelength range of 400 to 1200 nm to the blood vessel wall of the target site. The first light within this wavelength range has the effect of repairing the vascular endothelium and soothing the smooth muscle. After the first light is applied for a certain period of time, the blood vessel wall can maintain an expanded state for a sufficient time, which can ensure that the blood vessel wall does not rebound during the delivery of the therapeutic agent. The first light also has the effect of repairing the vascular endothelium, which can inhibit the occurrence of late vascular restenosis.

[0061] The blocking assembly 150 includes a first balloon 151 and a second balloon 152. In the working state, the first balloon 151 and the second balloon 152 are respectively located upstream and downstream of the blood flow direction to temporarily block the blood flow. Figure 1b , Figure 2b , Figure 3 , Figure 4 As shown, the outer sheath 110 has a therapeutic substance delivery channel 112 inside; the blocking component 150 includes:

[0062] A first balloon 151 is located at the periphery of the distal end of the outer sheath 110;

[0063] The second balloon 152, the distal end of the tube assembly has an extension portion extending out of the outer sheath 110, the second balloon 152 is located at the periphery of the extension portion, the first balloon 151 and the second balloon 152 are respectively located upstream and downstream of the expected delivery position of the therapeutic substance along the blood flow direction.

[0064] The first balloon 151 and the second balloon 152 are filled with fluid, and when in an inflated state, the blood flow is temporarily blocked, that is, a space without blood flow is created between the first balloon 151 and the second balloon 152, corresponding to the expected delivery position of the therapeutic substance. The order of inflating the first balloon 151 and the second balloon 152 depends on the direction of the blood flow, and the balloon closer to the upstream position of the blood flow is inflated first to block the blood flow.

[0065] See also Figure 3 , Figure 4 As shown, a first fluid channel 111 is provided in the side wall of the outer sheath 110 and is communicated with the first balloon 151, for delivering fluid to the first balloon 151. The first fluid channel 111 extends along the axial direction of the outer sheath 110 to the proximal end of the outer sheath 110.

[0066] See also Figure 3 , Figure 4As shown, a therapeutic substance delivery channel 112 is provided on the side wall of the outer sheath 110 , and the therapeutic substance delivery channel 112 extends along the axial direction of the outer sheath 110 to the proximal end of the outer sheath 110 , and the distal end of the therapeutic substance delivery channel 112 is open to deliver the drug to the intended delivery position of the therapeutic substance.

[0067] See also Figure 1a , Figure 2a , Figure 3 As shown, the proximal end of the outer sheath 110 is connected to a first handle 171 , and the first handle 171 is provided with: a first interface 1711 connected to the first fluid channel 111 , a second interface 1712 for passing through the tube assembly 130 , and a third interface 1713 connected to the therapeutic substance delivery channel 112 .

[0068] See also Figure 1b , Figure 2b , Figure 4 As shown, the outer sheath 110 is a double-layer tube structure and has an inner cavity 113 and an outer cavity 114 which are radially opposite to each other, wherein the inner cavity 113 serves as a channel for the tube assembly 130, and the outer cavity 114 separates and forms a first fluid channel 111 for delivering fluid to the first balloon 151 and a therapeutic substance delivery channel 112 for delivering the therapeutic substance to the intended delivery position of the therapeutic substance.

[0069] The outer cavity 114 separates and forms the first fluid channel 111 and the therapeutic substance delivery channel 112 , that is, the first fluid channel 111 and the therapeutic substance delivery channel 112 are independent of each other, and a part of the space of the outer cavity 114 is used as the first fluid channel 111 , and the other part of the space is used as the therapeutic substance delivery channel 112 .

[0070] See also Figure 4 As shown, a developing ring 192 is fixedly sleeved on the outer sheath 110 . The developing ring 192 is made of metal and can indicate the position of the first balloon 151 under the action of a developer.

[0071] The support frame 120 is made of memory material, and after being exposed to the outer sheath 110, it switches from a loaded state to an expanded state by self-expansion. The structure of the support frame 120 can be in various forms, such as Figure 7 In the illustrated embodiment, the cylindrical structure of the support frame 120 is in the shape of a hollow grid.

[0072] See also Figure 5 As shown, the tube assembly 130 includes:

[0073] An inner tube 131 , the lumen of the inner tube 131 providing a guide wire channel 180 ;

[0074] The outer tube 132 is sleeved on the outside of the inner tube 131, and the distal end of the outer tube 132 is connected to the second balloon 152. The radial gap between the outer tube 132 and the inner tube 131 serves as a second fluid channel 133 connected to the second balloon 152. The support frame 120 is located in the radial gap between the outer tube 132 and the outer sheath 110, and the proximal end of the support frame 120 is converged and extends out of the proximal end of the outer sheath 110.

[0075] When the support frame 120 is in the loading state ( Figure 5 , Figure 6 The support frame 120 is shown in a loaded state), the support frame 120 and the outer tube 132 are simultaneously stored in the outer sheath 110, and when the outer tube 132 extends out of the outer sheath 110, the support frame 120 moves out of the outer sheath 110 along with the outer tube 132, and the support frame 120 switches from the expansion state to the expanded state.

[0076] See also Figure 5 , Figure 6 As shown, the proximal side of the tube assembly 130 is connected to the second handle 172 , and the second handle 172 is provided with a fourth interface 1721 connected to the guidewire channel 180 , and a fifth interface 1722 connected to the second fluid channel 133 .

[0077] See also Figure 5 , Figure 6 As shown, a developing ring 192 is fixed on the inner tube 131 . The developing ring 192 is made of metal and can indicate the position of the second balloon 152 under the action of a developer.

[0078] The distal end of the support frame 120 can slide relative to the outer tube 132. In order to prevent the distal end of the support frame 120 from causing damage to the outer tube 132 wall when sliding, a support sleeve is slidably mounted on the outer periphery of the outer tube 132, and the distal end of the support frame 120 is connected to the support sleeve. The support sleeve enables the distal end of the support frame 120 and the outer tube 132 to slide relative to each other.

[0079] See also Figure 8 , Fig. 9 As shown, the light emitting component 140 is an optical fiber or a Micro LED, and the light emitting component 140 is located in the radial gap between the inner tube 131 and the outer tube 132. The light emitting component 140 is fixed to the outer wall of the inner tube 131 and extends toward the proximal end along the second fluid channel 133.

[0080] When using optical fiber, a laser generator is required. When using Micro LED, a power supply is required. The power supply can use miniaturized components such as button batteries to make the balloon catheter device lightweight as a whole.

[0081] The wavelength of the first light is in the range of 600 to 850 nm. The wavelength of the first light has an impact on the treatment effect, and the preferred wavelengths include 635 nm, 650 nm, or 808 nm. The wavelength of the first light is not fixed during the treatment process, and the wavelength can be adjusted according to the progress of the treatment. For example, at the beginning of the treatment, a shorter wavelength band can be selected, and in the middle of the treatment, a longer wavelength band can be selected.

[0082] The therapeutic substance delivery device 100 generally comprises:

[0083] Working state, in which each balloon (including the first balloon 151 and the second balloon 152) is inflated with fluid and exposed to the outer sheath 110, the support frame 120 is exposed to the outer sheath 110 in an expanded state or the working part of the light-emitting component 140 is at the expected delivery position of the therapeutic substance to emit light;

[0084] Delivery state. In the delivery state, each balloon (including the first balloon 151 and the second balloon 152) is folded in shape and housed in the outer sheath 110, the support frame 120 is housed in the outer sheath and is in a loading state or the light-emitting component 140 is housed in the outer sheath 110 and does not emit light.

[0085] Working status Figure 1a , Figure 1b , Figure 2a , Figure 2b As shown, Figure 1a , Figure 1b , Figure 2a , Figure 2b The first balloon 151 and the second balloon 152 are inflated with fluid, and the support frame 120 is in an expanded state and both are exposed to the outer sheath 110 .

[0086] The present application also provides a delivery system for delivering a therapeutic substance into a blood vessel, comprising:

[0087] The therapeutic substance delivery device 100 of the present application;

[0088] A first perfusion device, used to provide a therapeutic substance to be delivered into the blood vessel and communicated with the therapeutic substance delivery channel 112;

[0089] The second perfusion device is connected to the first balloon 151 and the second balloon 152 respectively through a fluid pipeline.

[0090] The first balloon 151 and the second balloon 152 can be connected to the same second perfusion device through a fluid pipeline, and the perfusion of the first balloon 151 and the second balloon 152 can be independently controlled. Alternatively, the first balloon 151 and the second balloon 152 can be respectively configured with their own perfusion devices.

[0091] The therapeutic substance delivered into the blood vessel includes pentagalloyl glucose, which is a phenolic compound with multiple phenolic groups and can cross-link elastin in the blood vessels in vivo to stabilize the blood vessels.

[0092] The present application also provides a method for deploying a vascular treatment, comprising:

[0093] Temporarily block blood flow upstream and downstream of a designated location along the direction of blood flow;

[0094] Expand at a designated site where a vascular treatment is expected to be delivered to maintain the spatial shape of the designated site;

[0095] Releases therapeutic substances to the designated area and maintains the predetermined treatment time.

[0096] First, at the designated site where the vascular treatment is expected to be delivered, the blood flow is temporarily blocked upstream and downstream of the designated site using an occluding component. Secondly, the blood vessel is dilated using a support frame or a light-emitting component. Finally, the treatment is delivered to the designated site.

[0097] A support frame or a light-emitting component is used to dilate the blood vessels to keep the blood vessels in the necessary dilated shape, and then a therapeutic substance is delivered into the blood vessels. The vascular therapeutic substance is pentagalloylglucose, which can cross-link the elastin in the blood vessels.

[0098] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0099] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims.

Claims

1. An interventional therapeutic delivery device, characterized in that: include: An outer sheath is a tubular structure having a distal end and a proximal end opposite to each other, and an inner portion of the outer sheath has a therapeutic substance delivery channel; a tube assembly, movably disposed in the outer sheath; The blocking component includes a first balloon and a second balloon which are sequentially arranged along the axis direction of the outer sheath and are used to temporarily block the blood flow, and the area between the first balloon and the second balloon is the expected delivery position of the therapeutic substance; A holding component is used to keep the blood vessel at the intended delivery position of the therapeutic substance in an expanded state, wherein the holding component adopts one of the following structures: a. A support frame, which is a radially deformable cylindrical structure as a whole, and has a loaded state in which it can be accommodated in the outer sheath and an expanded state exposed to the distal side of the outer sheath; b. A light-emitting component fixed to the tube assembly, wherein the light-emitting component has a working portion located within the expected delivery position of the therapeutic substance, and the working portion is used to output a first light with a wavelength range of 400 to 1200 nm.

2. The interventional therapeutic delivery device according to claim 1, characterized in that: The wavelength of the first light is in the range of 600-850 nm.

3. The interventional therapeutic delivery device according to claim 1, characterized in that: The first balloon is located at the periphery of the distal end of the outer sheath; The second balloon, the distal end of the tube assembly has an extension portion extending out of the outer sheath, the second balloon is located at the periphery of the extension portion, and the first balloon and the second balloon are respectively located upstream and downstream of the expected delivery position of the therapeutic substance along the blood flow direction.

4. The interventional therapeutic delivery device according to claim 3, characterized in that: A first fluid channel connected to the first balloon is provided in the side wall of the outer sheath for conveying fluid to the first balloon.

5. The interventional therapeutic delivery device according to claim 3, characterized in that: The outer sheath is a double-layer tube structure and has an inner cavity and an outer cavity opposite to each other in the radial direction, wherein the inner cavity serves as a channel of the tube assembly, and the outer cavity separates and forms a first fluid channel for delivering fluid to the first balloon and a therapeutic substance delivery channel for delivering the therapeutic substance to the intended delivery position of the therapeutic substance.

6. The interventional therapeutic delivery device according to claim 1, characterized in that: The support frame is made of memory material, and the cylindrical structure of the support frame is a hollow grid shape. After being exposed to the outer sheath, it switches from a loaded state to an expanded state by self-expansion.

7. The interventional therapeutic delivery device according to claim 3, characterized in that: The tube assembly comprises: an inner tube, the lumen of the inner tube providing a guide wire passage; The outer tube is sleeved on the outside of the inner tube, the distal end of the outer tube is connected to the second balloon, and the radial gap between the outer tube and the inner tube serves as a second fluid channel connected to the second balloon.

8. The interventional therapeutic delivery device according to claim 1, characterized in that: The light-emitting component is an optical fiber or a Micro LED, and is located in a radial gap between the inner tube and the outer tube. The light-emitting component is fixed to the outer wall of the inner tube and extends toward the proximal end along the second fluid channel.

9. The interventional therapeutic delivery device according to claim 1, characterized in that: The therapeutic substance delivery device generally comprises: Working state, in which each balloon is inflated with fluid and exposed to the outer sheath, the support frame is exposed to the outer sheath in an expanded state, or the working part of the light-emitting component is at the expected delivery position of the therapeutic substance to emit light; Delivery state, in the delivery state, the shapes of the balloons are folded and stored in the outer sheath, the support frame is stored in the outer sheath and is in a loading state, or the light-emitting component is stored in the outer sheath and does not emit light.

10. A delivery system for therapeutic substances based on an interventional approach, characterized in that: include: The therapeutic substance delivery device according to any one of claims 1 to 9; a first perfusion device, used for providing a therapeutic substance to be delivered into the blood vessel and connected to the therapeutic substance delivery channel; The second perfusion device is connected to the first balloon and the second balloon respectively through fluid pipelines.

Citation Information

Patent Citations

  • Double-balloon catheter with self-perfusion function

    CN110548212A

  • Combined balloon catheter

    CN117177793A

  • Delivery device and delivery system for delivering therapeutic substance into blood vessel

    CN223183903U

  • Guidewire loaded stent for delivery through a catheter

    US20030163156A1

  • Light delivery catheter

    US20040093044A1